We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Recro Pharma was granted a March 2019 PDUFA date for its non-opioid pain drug after providing the FDA with additional data and answering manufacturing questions raised in a complete response letter.